Date published: 2026-5-22

1-800-457-3801

SCBT Portrait Logo
Seach Input

Heptakis(2,6-di-O-methyl)-β-cyclodextrin (CAS 51166-71-3)

0.0(0)
Write a reviewAsk a question

Alternate Names:
Di-O-methyl-beta-cyclodextrin
Application:
Heptakis(2,6-di-O-methyl)-β-cyclodextrin is a cholesterol sequestering cyclodextrin preparation
CAS Number:
51166-71-3
Molecular Weight:
1331.36
Molecular Formula:
C56H98O35
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Heptakis(2,6-di-O-methyl)-β-cyclodextrin is a chemically modified cyclic oligosaccharide used extensively in various fields of research. This compound is particularly valuable in the study of molecular encapsulation, where it is used to investigate the inclusion of various hydrophobic molecules within its cavity, thereby improving their solubility and stability. In the realm of analytical chemistry, Heptakis(2,6-di-O-methyl)-β-cyclodextrin serves as a chiral stationary phase in chromatography, aiding in the separation of enantiomers. Furthermore, it is used in the investigation of drug delivery systems, where its ability to form host-guest complexes is explored to potentially increase the bioavailability of poorly soluble chemicals. Research involving this cyclodextrin derivative sheds light on the fundamental interactions between cyclodextrins and guest molecules, which is critical for the development of advanced materials and techniques in various scientific disciplines.


Heptakis(2,6-di-O-methyl)-β-cyclodextrin (CAS 51166-71-3) References

  1. Structure of the complex of heptakis(2,6-di-O-methyl)-beta-cyclodextrin with (2,4-dichlorophenoxy)acetic acid.  |  Tsorteki, F. and Mentzafos, D. 2002. Carbohydr Res. 337: 1229-33. PMID: 12110198
  2. Combining magnetic resonance spectroscopies, mass spectrometry, and molecular dynamics: investigation of chiral recognition by 2,6-di-O-methyl-beta-cyclodextrin.  |  Franchi, P., et al. 2004. J Am Chem Soc. 126: 4343-54. PMID: 15053624
  3. Evaluation of the cytotoxicity of beta-cyclodextrin derivatives: evidence for the role of cholesterol extraction.  |  Kiss, T., et al. 2010. Eur J Pharm Sci. 40: 376-80. PMID: 20434542
  4. Inclusion interaction of chloramphenicol and heptakis (2,6-di-O-methyl)-β-cyclodextrin: phase solubility and spectroscopic methods.  |  Shi, JH. and Zhou, YF. 2011. Spectrochim Acta A Mol Biomol Spectrosc. 83: 570-4. PMID: 21945123
  5. Heptakis(2,6-di-O-methyl)-beta-cyclodextrin complexation with the antitumor agent chlorambucil.  |  Green, AR. and Guillory, JK. 1989. J Pharm Sci. 78: 427-31. PMID: 2746481
  6. Formation, characterization and pH dependence of rifampicin: heptakis(2,6-di-O-methyl)-β-cyclodextrin complexes.  |  Angiolini, L., et al. 2017. Int J Pharm. 531: 668-675. PMID: 28596140
  7. The Interaction of Heptakis (2,6-di-O-Methyl)-β-cyclodextrin with Mianserin Hydrochloride and Its Influence on the Drug Toxicity.  |  Belica-Pacha, S., et al. 2021. Int J Mol Sci. 22: PMID: 34502332

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Heptakis(2,6-di-O-methyl)-β-cyclodextrin, 1 g

sc-215141
1 g
$101.00

Heptakis(2,6-di-O-methyl)-β-cyclodextrin, 5 g

sc-215141A
5 g
$193.00

Heptakis(2,6-di-O-methyl)-β-cyclodextrin, 10 g

sc-215141B
10 g
$346.00

Heptakis(2,6-di-O-methyl)-β-cyclodextrin, 25 g

sc-215141C
25 g
$678.00

Heptakis(2,6-di-O-methyl)-β-cyclodextrin, 100 g

sc-215141D
100 g
$2039.00